Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Cited In for PubMed (Select 20212250)

1.

Clinical experiences with molecular targeted therapy in lung cancer in China.

Wang Y, Sun Y.

Thorac Cancer. 2015 Jul;6(4):379-84. doi: 10.1111/1759-7714.12243. Epub 2015 Apr 22. Review.

2.

Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.

Liu Y, Wang P, Li S, Yin L, Shen H, Liu R.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):3027-35. eCollection 2015.

3.

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.

Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL.

BMC Cancer. 2015 May 1;15:339. doi: 10.1186/s12885-015-1350-6.

4.

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Chan BA, Hughes BG.

Transl Lung Cancer Res. 2015 Feb;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01. Review.

5.

Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial.

Mendivil AN, Rodriguez PM, Felip E.

Transl Lung Cancer Res. 2013 Feb;2(1):E13-6. doi: 10.3978/j.issn.2218-6751.2012.09.12. No abstract available.

6.

Antiangiogenic tyrosine kinase inhibitors in non-small-cell-lung cancer: lights and shadows.

Gasparini G.

Transl Lung Cancer Res. 2013 Feb;2(1):E10-2. doi: 10.3978/j.issn.2218-6751.2012.08.04. No abstract available.

7.

Targeting angiogenesis in lung cancer - Pitfalls in drug development.

Hilbe W, Manegold C, Pircher A.

Transl Lung Cancer Res. 2012 Jun;1(2):122-8. doi: 10.3978/j.issn.2218-6751.2012.01.01. Review.

8.

Pulmonary squamous cell carcinoma and sorafenib.

Gollard R, Garcia D, Natale R.

Clin Case Rep. 2014 Oct;2(5):206-8. doi: 10.1002/ccr3.95. Epub 2014 Jul 25.

9.

Novel agents in development for advanced non-small cell lung cancer.

Stinchcombe TE.

Ther Adv Med Oncol. 2014 Sep;6(5):240-53. doi: 10.1177/1758834014532510. Review. Erratum in: Ther Adv Med Oncol. 2015 Jul;7(4):237.

10.

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.

Hong S, Fang W, Liang W, Yan Y, Zhou T, Qin T, Wu X, Ma Y, Zhao Y, Yang Y, Hu Z, Xue C, Hou X, Chen Y, Huang Y, Zhao H, Zhang L.

Onco Targets Ther. 2014 Oct 7;7:1851-67. doi: 10.2147/OTT.S68386. eCollection 2014.

11.

Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.

Liang W, Wu X, Hong S, Zhang Y, Kang S, Fang W, Qin T, Huang Y, Zhao H, Zhang L.

PLoS One. 2014 Oct 16;9(10):e109757. doi: 10.1371/journal.pone.0109757. eCollection 2014.

12.

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

Socinski MA.

Curr Oncol. 2014 Oct;21(5):e691-703. doi: 10.3747/co.21.1997. Review.

13.

Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel).

Blais N, Hirsh V.

Front Oncol. 2014 Jul 21;4:177. doi: 10.3389/fonc.2014.00177. eCollection 2014. Review. Erratum in: Front Oncol. 2014;4:300.

14.

Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.

Al-Farsi A, Ellis PM.

Front Oncol. 2014 Jun 27;4:157. doi: 10.3389/fonc.2014.00157. eCollection 2014. Review.

15.

RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.

Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J.

J Clin Invest. 2014 Aug;124(8):3601-11. doi: 10.1172/JCI74134. Epub 2014 Jul 8.

16.

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer.

Belani CP, Yamamoto N, Bondarenko IM, Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG, Ingrosso A, Kim S, Scagliotti GV.

BMC Cancer. 2014 Apr 25;14:290. doi: 10.1186/1471-2407-14-290.

17.
18.

Targeting angiogenesis in squamous non-small cell lung cancer.

Piperdi B, Merla A, Perez-Soler R.

Drugs. 2014 Mar;74(4):403-13. doi: 10.1007/s40265-014-0182-z. Review.

19.

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM, Agorreta J.

EMBO Mol Med. 2014 Apr;6(4):539-50. doi: 10.1002/emmm.201303214. Epub 2014 Feb 5.

20.

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA; Alliance for Clinical Trials in Oncology.

J Thorac Oncol. 2014 Feb;9(2):214-21. doi: 10.1097/JTO.0000000000000071.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk